Amplicon rescued miltiplex PCR service

PRE-SOLICITATION NOTICE NOI 1970275

This is a Notice of intent, not a request for proposal. The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) intends to negotiate on another than full and open competition basis with iRepertoire Inc. for custom amplicon rescued multiplex PCR service.

LMIV Vaccine Development Unit develops and performs clinical evaluation of prototype malaria vaccines. Each candidate vaccine has to undergo a rigorous development process that requires the input of many highly skilled scientists with specific areas of expertise. These include creation of expression systems, fermentation optimization, scale-up of purification technology, clinical good manufacturing practices (cGMP) production, formulation, quality control, preclinical testing, and clinical trials. iRepertoire will perform characterization of B cell receptors generated in response to vaccination with Pfs230 malaria transmission blocking vaccine in Malian adults using their novel, patented multiplex PCR technology (Patent No 7,999,092). The Place of performance is 9000 Rockville Pike, Bethesda, MD 20892.

The statutory authority for this sole source requirement is 41 U.S.C.1901 (e) (2) as implemented by FAR 13.106-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL. All responsible sources that could provide comparable services may submit a capability statement that will be considered by email (subject line to reference NOI-NIAID-1970275) to Angela Stanton at angela.stanton(ci)nih.gov, by 5:00 pm eastern standard time 5:00 PM eastern standard time, June 7, 2019. All responses received by the closing date ofthis synopsis will be considered by the Government. A detennination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.

.